Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII

Muenzer, 2006, A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome), Genet. Med., 8, 465, 10.1097/01.gim.0000232477.37660.fb Sly, 1973, Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis, J. Pediatr., 82, 249, 10.1016/S0022-3476(73)80162-3 McCafferty, 2019, Vestronidase alfa: a review in mucopolysaccharidosis, 33, 233 Tomatsu, 2009, Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly syndrome), Hum. Mutat., 30, 511, 10.1002/humu.20828 Holtz, 2020, Association between mucopolysaccharidosis type VII and hydrops fetalis, Ultrasound Obstet. Gynecol., 55, 416, 10.1002/uog.20371 Kakkis, 2001, Enzyme-replacement therapy in mucopolysaccharidosis I, N. Engl. J. Med., 344, 182, 10.1056/NEJM200101183440304 Wraith, 2007, Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase), Pediatrics, 120, e37, 10.1542/peds.2006-2156 Wraith, 2004, Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase), J. Pediatr., 144, 581, 10.1016/j.jpeds.2004.01.046 Harmatz, 2006, J. Pediatr., 148, 533, 10.1016/j.jpeds.2005.12.014 Jones, 2020, Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses, Mol. Genet. Metab., 130, 255, 10.1016/j.ymgme.2020.06.004 Melbouci, 2018, Growth impairment in mucopolysaccharidoses, Mol. Genet. Metab., 124, 1, 10.1016/j.ymgme.2018.03.004 Różdżyńska-Świątkowska, 2016, Bioimpedance analysis as a method to evaluate the proportion of fatty and muscle tissues in progressive myopathy in Pompe disease, JIMD Rep., 26, 45, 10.1007/8904_2015_473 Montaño, 2016, Clinical course of Sly syndrome (mucopolysaccharidosis type VII), J. Med. Genet., 53, 403, 10.1136/jmedgenet-2015-103322 O’Connor, 1998, Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function, J. Clin. Invest., 101, 1394, 10.1172/JCI1773 Vogler, 1998, Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease, J. Inherit. Metab. Dis., 21, 575, 10.1023/A:1005423222927 Vogler, 1996, Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival, Pediatr. Res., 39, 1050, 10.1203/00006450-199606000-00019 Harmatz, 2018, A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease, Mol. Genet. Metab., 123, 488, 10.1016/j.ymgme.2018.02.006 Wang, 2020, The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII, Mol. Genet. Metab., 129, 219, 10.1016/j.ymgme.2020.01.003 Gabrielli, 2016, 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment, BMC Med. Genet., 17, 19, 10.1186/s12881-016-0284-4 Lampe, 2014, Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age, JIMD Rep., 14, 99, 10.1007/8904_2013_289 Laraway, 2016, Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I, J. Pediatr., 178, 219, 10.1016/j.jpeds.2016.08.033 McGill, 2010, Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age—a sibling control study, Clin. Genet., 77, 492, 10.1111/j.1399-0004.2009.01324.x Tajima, 2013, Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings, Mol. Genet. Metab., 108, 172, 10.1016/j.ymgme.2012.12.010 Tylki-Szymanska, 2012, Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up, Acta Paediatr., 101, e42, 10.1111/j.1651-2227.2011.02385.x Rosenberg, 1991, Normal splenic size in infants and children: sonographic measurements, AJR Am. J. Roentgenol., 157, 119, 10.2214/ajr.157.1.2048509 Dhingra, 2010, Normal values of liver and spleen size by ultrasonography in Indian children, Ind. Pediatr., 47, 487, 10.1007/s13312-010-0090-6 Busner, 2007, The clinical global impressions scale: applying a research tool in clinical practice, Psychiatry (Edgmont.), 4, 28 Bayley, 2006 Tanner, 1985, Clinical longitudinal standards for height and height velocity for North American children, J. Pediatr., 107, 317, 10.1016/S0022-3476(85)80501-1 Komosinska-Vassev, 2014, Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population, Clin. Biochem., 47, 1341, 10.1016/j.clinbiochem.2014.06.012 Beaudet, 1975, Variation in the phenotypic expression of β-glucuronidase deficiency, J. Pediatr., 86, 388, 10.1016/S0022-3476(75)80968-1 Gillett, 2001, Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly, J. Pediatr. Gastroenterol. Nutr., 33, 216, 10.1097/00005176-200108000-00025 Lee, 1985, Beta-glucuronidase deficiency. A heterogeneous mucopolysaccharidosis, Am. J. Dis. Child., 139, 57, 10.1001/archpedi.1985.02140030059029 Staretz-Chacham, 2009, Lysosomal storage disorders in the newborn, Pediatrics, 123, 1191, 10.1542/peds.2008-0635 Vervoort, 1996, Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII, Am. J. Hum. Genet., 58, 457